258 related articles for article (PubMed ID: 30871628)
1. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
[TBL] [Abstract][Full Text] [Related]
2. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
Erbe AK; Wang W; Reville PK; Carmichael L; Kim K; Mendonca EA; Song Y; Hank JA; London WB; Naranjo A; Hong F; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Miller JS; Gilman AL; Kahl B; Yu AL; Sondel PM
Front Immunol; 2017; 8():675. PubMed ID: 28659916
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
4. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
Thöns C; Senff T; Hydes TJ; Manser AR; Heinemann FM; Heinold A; Heilmann M; Kim AY; Uhrberg M; Scherbaum N; Lauer GM; Khakoo SI; Timm J
J Hepatol; 2017 Sep; 67(3):462-470. PubMed ID: 28412292
[TBL] [Abstract][Full Text] [Related]
5. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.
Naumova E; Mihaylova A; Stoitchkov K; Ivanova M; Quin L; Toneva M
Cancer Immunol Immunother; 2005 Feb; 54(2):172-8. PubMed ID: 15248031
[TBL] [Abstract][Full Text] [Related]
7. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
[TBL] [Abstract][Full Text] [Related]
8. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.
Keating SE; Ní Chorcora C; Dring MM; Stallings RL; O'Meara A; Gardiner CM
Tissue Antigens; 2015 Sep; 86(3):172-7. PubMed ID: 26202659
[TBL] [Abstract][Full Text] [Related]
9. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
10. The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.
Kiani Z; Dupuy FP; Bruneau J; Lebouché B; Retière C; Geraghty DE; Bernard NF
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511383
[TBL] [Abstract][Full Text] [Related]
11. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
[TBL] [Abstract][Full Text] [Related]
12. Decreased interferon-γ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection.
Mele D; Pasi A; Cacciatore R; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Liver Int; 2019 Jul; 39(7):1237-1245. PubMed ID: 31177636
[TBL] [Abstract][Full Text] [Related]
13. KIR3DL1+HLA-B Bw4Ile80 and KIR2DS1+HLA-C2 combinations are both associated with ankylosing spondylitis in the Iranian population.
Tajik N; Shahsavar F; Poormoghim H; Radjabzadeh MF; Mousavi T; Jalali A
Int J Immunogenet; 2011 Oct; 38(5):403-9. PubMed ID: 21797986
[TBL] [Abstract][Full Text] [Related]
14. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Feils AS; Erbe AK; Birstler J; Kim K; Hoch U; Currie SL; Nguyen T; Yu D; Siefker-Radtke AO; Tannir N; Tolaney SM; Diab A; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2099-2111. PubMed ID: 36823323
[TBL] [Abstract][Full Text] [Related]
15. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis.
Mahmoudi M; Fallahian F; Sobhani S; Ghoroghi S; Jamshidi A; Poursani S; Dolati M; Hosseinpour Z; Gharibdoost F
Clin Rheumatol; 2017 Apr; 36(4):853-862. PubMed ID: 28120169
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians.
Maruthamuthu S; Rajalingam R; Pandian K; Madasamy S; Manoharan M; Pitchai L; Murugesan A; Mariakuttikan J
AIDS; 2018 Nov; 32(18):2679-2688. PubMed ID: 30289808
[TBL] [Abstract][Full Text] [Related]
17. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
18. HLA alleles determine differences in human natural killer cell responsiveness and potency.
Kim S; Sunwoo JB; Yang L; Choi T; Song YJ; French AR; Vlahiotis A; Piccirillo JF; Cella M; Colonna M; Mohanakumar T; Hsu KC; Dupont B; Yokoyama WM
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3053-8. PubMed ID: 18287063
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis.
Littera R; Chessa L; Onali S; Figorilli F; Lai S; Secci L; La Nasa G; Caocci G; Arras M; Melis M; Cappellini S; Balestrieri C; Serra G; Conti M; Zolfino T; Casale M; Casu S; Pasetto MC; Barca L; Salustro C; Matta L; Scioscia R; Zamboni F; Faa G; Orrù S; Carcassi C
PLoS One; 2016; 11(1):e0146086. PubMed ID: 26744892
[TBL] [Abstract][Full Text] [Related]
20. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
